Company intelligence / Profile preview
Phanes Biotech
Malvern, Pennsylvania, United Statesphanesbiotech.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Phanes Biotech has developed two lead programs for Alzheimer’s disease and related neurodegenerative disorders. PB021, a peptidergic small molecule, has shown preclinical efficacy in preventing neuronal destruction and promoting neuroregeneration. PB43D, a monoclonal antibody targeting tau pathology, also reduces amyloid beta pathology. The company aims to initiate Phase I/II clinical trials in AD patients. No published human clinical results as of June 2025.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Veravas (strategic partnership for development/licensing)
Beyond the preview
Go deeper on Phanes Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phanes Biotech.